Inventory

9 Months Ended

Sep. 30, 2019

Inventory Disclosure [Abstract]

Inventory

(4) Inventory

The Company capitalizes its purchases of saleable inventory of Vascepa from suppliers that have been qualified by the FDA. Inventories as of September 30, 2019 and December 31, 2018 consist of the following:

In thousands	September 30, 2019			December 31, 2018
Raw materials	$	14,772		$	14,142
Work in process		11,909			8,590
Finished goods		28,034			35,357
Total inventory, gross		54,715			58,089
Inventory cost adjustment		(158	)		(287	)
Inventory	$	54,557		$	57,802